Active Biotech enters into global patent license agreement with Oncode Institute for tasquinimod in myelofibrosis
February 09, 2022 03:30 ET | Active Biotech
Lund, February 9, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced it has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to...
Active Biotech ingår globalt patentlicensavtal med Oncode Institute för tasquinimod i myelofibros
February 09, 2022 03:30 ET | Active Biotech
Lund, 9 februari 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) meddelar idag att man har ingått ett exklusivt licensavtal med Oncode Institute i Rotterdam, Nederländerna, för de globala rättigheterna...
Active Biotech announces first patient dosed in the combination part of the phase Ib/IIa study of tasquinimod in multiple myeloma
February 07, 2022 02:30 ET | Active Biotech
Lund Sweden, February 7, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the first patient has been dosed in the combination part of the phase Ib/IIa clinical study of tasquinimod...
Active Biotech meddelar att första patienten doserats i kombinationsdelen av fas Ib/IIa-studien av tasquinimod i multipelt myelom
February 07, 2022 02:30 ET | Active Biotech
Lund 7 februari 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) tillkännager idag att den första patienten har doserats i kombinationsdelen av den kliniska fas Ib/IIa-studien av tasquinimod vid...
Active Biotech Appoints Erik Vahtola as Chief Medical Officer
January 04, 2022 08:00 ET | Active Biotech
Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022. He will join...
Active Biotech utser Erik Vahtola till Chief Medical Officer
January 04, 2022 08:00 ET | Active Biotech
Lund, 4 januari 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) tillkännagav idag att Dr. Erik Vahtola, MD, PhD, har utsetts till Chief Medical Officer (CMO), från och med 1 januari 2022. Han kommer...
Preclinical tasquinimod data presented at ASH 2021 available on Active Biotech’s website
December 15, 2021 10:00 ET | Active Biotech
Lund, December 15, 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that preclinical data on its candidate drug tasquinimod, a small molecule immunomodulator, are now available on the...
Prekliniska data kring tasquinimod som presenterades vid ASH 2021 finns tillgängliga på Active Biotechs hemsida
December 15, 2021 10:00 ET | Active Biotech
Lund, 15 december 2021 - Active Biotech (NASDAQ STOCKHOLM: ACTI) tillkännager idag att prekliniska data kring tasquinimod, en småmolekulär immunmodulator, finns nu tillgängliga på företagets hemsida....
Active Biotech's nomination committee appointed
December 10, 2021 07:00 ET | Active Biotech
In accordance with a decision made by the Annual General Meeting held on May 19, 2021, the Nomination Committee shall comprise the representatives for the three largest shareholders by votes, as per...
Active Biotechs valberedning utsedd
December 10, 2021 07:00 ET | Active Biotech
Enligt beslut från årsstämman den 19 maj 2021, ska valberedningen för Active Biotech bestå av representanter för de, i slutet av september månad 2021, röstmässigt tre största ägarna, samt styrelsens...